{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T04:28:12Z","timestamp":1783830492406,"version":"3.55.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12072-013-9495-3","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T10:54:04Z","timestamp":1388660044000},"page":"39-54","source":"Crossref","is-referenced-by-count":8,"title":["Loss of HBsAg and antiviral treatment: from basics to clinical significance"],"prefix":"10.1007","volume":"8","author":[{"given":"Yuecheng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"issue":"4","key":"9495_CR1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","volume":"26","author":"CJ Chen","year":"2011","unstructured":"Chen CJ, Yang HI. Natural history of chronic hepatitis B revealed. J Gastroenterol Hepatol 2011;26(4):628\u2013638","journal-title":"J Gastroenterol Hepatol"},{"issue":"5 Suppl","key":"9495_CR2","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45\u2013S55","journal-title":"Hepatology"},{"issue":"5","key":"9495_CR3","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","volume":"53","author":"JM Lee","year":"2011","unstructured":"Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53(5):1486\u20131493","journal-title":"Hepatology"},{"issue":"7","key":"9495_CR4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2011.01465.x","volume":"18","author":"MJ Sonneveld","year":"2011","unstructured":"Sonneveld MJ, Zoutendijk R, Janssen HLA. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011;18(7):449\u2013457","journal-title":"J Viral Hepat"},{"issue":"12","key":"9495_CR5","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantification can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5(12):1462\u20131468","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"9495_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1478-3231.2010.02384.x","volume":"31","author":"MJ Sonneveld","year":"2011","unstructured":"Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int 2011;31(Suppl 1):78\u201384","journal-title":"Liver Int"},{"key":"9495_CR7","doi-asserted-by":"crossref","unstructured":"Gane E, Heathcote EJ, Marcellin P, et al. HBsAg kinetics of decay and baseline characteristics of HBsAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment. J Hepatol 2010;52(Suppl 1):S388","DOI":"10.1016\/S0168-8278(10)61007-0"},{"issue":"4","key":"9495_CR8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52(4):1232\u20131241","journal-title":"Hepatology"},{"issue":"3","key":"9495_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44(3):675\u2013684","journal-title":"Hepatology"},{"issue":"3","key":"9495_CR10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661\u2013662","journal-title":"Hepatology"},{"issue":"3","key":"9495_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcv.2011.04.005","volume":"51","author":"MJ Sonneveld","year":"2011","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51(3):175\u2013178","journal-title":"J Clin Virol"},{"issue":"5","key":"9495_CR12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jmv.21706","volume":"82","author":"S Louisirirotchanakul","year":"2010","unstructured":"Louisirirotchanakul S, Khupulsup K, Akraekthalin S, et al. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays. J Med Virol 2010;82(5):755\u2013762","journal-title":"J Med Virol"},{"issue":"3","key":"9495_CR13","doi-asserted-by":"crossref","first-page":"e32143","DOI":"10.1371\/journal.pone.0032143","volume":"7","author":"E Tuaillon","year":"2012","unstructured":"Tuaillon E, Mondain AM, Nagot N, et al. Comparison of serum HBsAg quantification by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS ONE 2012;7(3):e32143","journal-title":"PLoS ONE"},{"issue":"11","key":"9495_CR14","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.05122-11","volume":"18","author":"BJ Zacher","year":"2011","unstructured":"Zacher BJ, Moriconi F, Bowden S, et al. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol 2011;18(11):1943\u20131950","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"9495_CR15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jmv.22089","volume":"83","author":"MH Lee","year":"2011","unstructured":"Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011;83(7):1178\u20131186","journal-title":"J Med Virol"},{"issue":"1","key":"9495_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcv.2010.02.014","volume":"48","author":"W Cai","year":"2010","unstructured":"Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48(1):22\u201326","journal-title":"J Clin Virol"},{"issue":"5","key":"9495_CR17","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3\u00a0years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52(5):1611\u20131620","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"9495_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1440-1746.2010.06544.x","volume":"26","author":"HL Chan","year":"2011","unstructured":"Chan HL, Jia J. Chronic hepatitis B in Asia\u2014new insights from the past decade. J Gastroenterol Hepatol 2011;26(Suppl 1):131\u2013137","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"9495_CR19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","volume":"52","author":"T Nguyen","year":"2010","unstructured":"Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52(4):508\u2013513","journal-title":"J Hepatol"},{"issue":"6","key":"9495_CR20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51(6):1933\u20131944","journal-title":"Hepatology"},{"issue":"7","key":"9495_CR21","doi-asserted-by":"crossref","first-page":"e36349","DOI":"10.1371\/journal.pone.0036349","volume":"7","author":"S Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m S, Larsson SB, Hannoun C, Lindh M. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load-down-regulated transcription of PgRNA has limited impact. PLoS ONE 2012;7(7):e36349","journal-title":"PLoS ONE"},{"issue":"4","key":"9495_CR22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","volume":"52","author":"J Jaroszewicz","year":"2010","unstructured":"Jaroszewicz J. Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52(4):514\u2013522","journal-title":"J Hepatol"},{"issue":"3","key":"9495_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2(3):263\u2013283","journal-title":"Hepatol Int"},{"issue":"2","key":"9495_CR24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","volume":"139","author":"MR Brunetto","year":"2010","unstructured":"Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139(2):483\u2013490","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"9495_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","volume":"26","author":"CL Lin","year":"2011","unstructured":"Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123\u2013130","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"9495_CR26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48(2):335\u2013352","journal-title":"J Hepatol"},{"issue":"5","key":"9495_CR27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","volume":"45","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45(5):1187\u20131192","journal-title":"Hepatology"},{"issue":"3","key":"9495_CR28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/hep.25718","volume":"56","author":"WK Seto","year":"2012","unstructured":"Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56(3):812\u2013819","journal-title":"Hepatology"},{"issue":"2","key":"9495_CR29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2010.06.026","volume":"139","author":"BJ McMahon","year":"2010","unstructured":"McMahon BJ, Hepatitis B. surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life. Gastroenterology 2010;139(2):380\u2013382","journal-title":"Gastroenterology"},{"key":"9495_CR30","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2012. doi: 10.1002\/hep.26041 .","journal-title":"Hepatology"},{"issue":"4","key":"9495_CR31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135(4):1192\u20131199","journal-title":"Gastroenterology"},{"issue":"2","key":"9495_CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","volume":"42","author":"SH Ahn","year":"2005","unstructured":"Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42(2):188\u2013194","journal-title":"J Hepatol"},{"issue":"5","key":"9495_CR33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","volume":"51","author":"J Simonetti","year":"2010","unstructured":"Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51(5):1531\u20131537","journal-title":"Hepatology"},{"issue":"12","key":"9495_CR34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3748\/wjg.v17.i12.1563","volume":"17","author":"JL Lled\u00f3","year":"2011","unstructured":"Lled\u00f3 JL, Fern\u00e1ndez C, Guti\u00e9rrez ML, et al. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011;17(12):1563\u20131568","journal-title":"World J Gastroenterol"},{"issue":"2","key":"9495_CR35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135(2):459\u2013467","journal-title":"Gastroenterology"},{"issue":"10","key":"9495_CR36","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/ajg.2009.371","volume":"104","author":"EH Buster","year":"2009","unstructured":"Buster EH, Flink HJ, Simsek H, et al. Early HBeAg loss during peginterferon \u03b1-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am J Gastroenterol 2009;104(10):2449\u20132457","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"9495_CR37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","volume":"139","author":"JG Reijnders","year":"2010","unstructured":"Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139(2):491\u2013498","journal-title":"Gastroenterology"},{"issue":"5","key":"9495_CR38","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1053\/jhep.2001.28708","volume":"34","author":"J Hou","year":"2001","unstructured":"Hou J, Wang Z, Cheng J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001;34(5):1027\u20131034","journal-title":"Hepatology"},{"issue":"2","key":"9495_CR39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","volume":"101","author":"HJ Flink","year":"2006","unstructured":"Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101(2):297\u2013303","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"9495_CR40","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jmv.21519","volume":"81","author":"O Borgniet","year":"2009","unstructured":"Borgniet O, Parvaz P, Bouix C, et al. Clearance of Serum HBsAg and Anti-HBs Seroconversion Following Antiviral Therapy for Chronic Hepatitis B. J Med Virol 2009;81(8):1336\u20131342","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"9495_CR41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1478-3231.2010.02390.x","volume":"31","author":"R Moucari","year":"2011","unstructured":"Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011;31(Suppl 1):122\u2013128","journal-title":"Liver Int"},{"issue":"6","key":"9495_CR42","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137(6):2002\u20132009","journal-title":"Gastroenterology"},{"issue":"3","key":"9495_CR43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","volume":"54","author":"JGP Reijnders","year":"2011","unstructured":"Reijnders JGP, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54(3):449\u2013454","journal-title":"J Hepatol"},{"issue":"4","key":"9495_CR44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","volume":"49","author":"MR Brunetto","year":"2009","unstructured":"Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49(4):1141\u20131150","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"9495_CR45","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","volume":"49","author":"R Perrillo","year":"2009","unstructured":"Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S103\u2013S11","journal-title":"Hepatology"},{"issue":"4","key":"9495_CR46","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","volume":"52","author":"MJ Sonneveld","year":"2010","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52(4):1251\u20131257","journal-title":"Hepatology"},{"issue":"8","key":"9495_CR47","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3851\/IMP1458","volume":"14","author":"R Moucari","year":"2009","unstructured":"Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14(8):1183\u20131188","journal-title":"Antivir Ther"},{"issue":"4","key":"9495_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2012.04.015","volume":"54","author":"S Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m S, Eilard A, Larsson SB, et al. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. J Clin Virol 2012;54(4):321\u2013326","journal-title":"J Clin Virol"},{"issue":"1","key":"9495_CR49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","volume":"17","author":"RG Gish","year":"2010","unstructured":"Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17(1):16\u201322","journal-title":"J Viral Hepat"},{"issue":"1","key":"9495_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.24363","volume":"54","author":"CW Hsu","year":"2011","unstructured":"Hsu CW, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology 2011;54(1):101\u2013108","journal-title":"Hepatology"},{"issue":"10","key":"9495_CR51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2893.2012.01595.x","volume":"19","author":"CM Martin","year":"2012","unstructured":"Martin CM, Welge JA, Rouster SD, et al. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. J Viral Hepat 2012;19(10):716\u2013723","journal-title":"J Viral Hepat"},{"key":"9495_CR52","doi-asserted-by":"crossref","unstructured":"Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus\/hepatitis B virus coinfection: a meta-analysis. Virol J 2012;9(1):186 provisional","DOI":"10.1186\/1743-422X-9-186"},{"issue":"1","key":"9495_CR53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0676.2001.210107.x","volume":"21","author":"AB Nunen van","year":"2001","unstructured":"van Nunen AB, Pontesilli O, Uytdehaag F, et al. Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production. Liver 2001;21(1):45\u201349","journal-title":"Liver"},{"issue":"4","key":"9495_CR54","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0016-5085(92)91521-5","volume":"103","author":"KG Benner","year":"1992","unstructured":"Benner KG, Lee RG, Keeffe EB, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992;103(4):1307\u20131312","journal-title":"Gastroenterology"},{"issue":"5","key":"9495_CR55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00535-008-2165-x","volume":"43","author":"K Ojiro","year":"2008","unstructured":"Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn\u2019s disease treated using infliximab. J Gastroenterol 2008;43(5):397\u2013401","journal-title":"J Gastroenterol"},{"issue":"2","key":"9495_CR56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43(2):209\u2013220","journal-title":"Hepatology"},{"issue":"10","key":"9495_CR57","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/QAD.0b013e32810c8bcf","volume":"21","author":"L Piroth","year":"2007","unstructured":"Piroth L, S\u00e8ne D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007;21(10):1323\u20131331","journal-title":"AIDS"},{"issue":"1","key":"9495_CR58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/01.mpg.0000243439.47334.4e","volume":"44","author":"BH Choe","year":"2007","unstructured":"Choe BH, Lee JH, Jang YC, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-\u03b1 in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44(1):92\u201398","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"9495_CR59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","volume":"50","author":"K Wursthorn","year":"2011","unstructured":"Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011;50(4):292\u2013296","journal-title":"J Clin Virol"},{"issue":"3\u20134","key":"9495_CR60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0166-3542(94)90022-1","volume":"23","author":"HL Janssen","year":"1994","unstructured":"Janssen HL, Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha interferon therapy. Antiviral Res 1994;23(3\u20134):251\u2013257","journal-title":"Antiviral Res"},{"issue":"1","key":"9495_CR61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","volume":"51","author":"F B\u00f6mmel van","year":"2010","unstructured":"van B\u00f6mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues. Hepatology 2010;51(1):73\u201380","journal-title":"Hepatology"},{"issue":"1","key":"9495_CR62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350701200107","volume":"12","author":"EK Manesis","year":"2007","unstructured":"Manesis EK, Hadziyannis ES, Angelopoulou OP, et al. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007;12(1):73\u201382","journal-title":"Antivir Ther"},{"issue":"11\u201312","key":"9495_CR63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","volume":"32","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010;32(11\u201312):1323\u20131331","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"9495_CR64","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1440-1746.2010.06282.x","volume":"25","author":"H Ma","year":"2010","unstructured":"Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010;25(9):1498\u2013506","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"9495_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcv.2009.07.005","volume":"46","author":"P Tangkijvanich","year":"2009","unstructured":"Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009;46(2):117\u2013123","journal-title":"J Clin Virol"},{"issue":"8","key":"9495_CR66","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","volume":"105","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst V, ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010;105(8):1762\u20131769","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9495_CR67","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","volume":"49","author":"R Moucari","year":"2009","unstructured":"Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg negative patients. Hepatology 2009;49(4):1151\u20131157","journal-title":"Hepatology"},{"issue":"4","key":"9495_CR68","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/135965350801300402","volume":"13","author":"J Wiegand","year":"2008","unstructured":"Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008;13(4):547\u2013554","journal-title":"Antivir Ther"},{"issue":"2","key":"9495_CR69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","volume":"15","author":"CM Chu","year":"2010","unstructured":"Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15(2):133\u2013143","journal-title":"Antivir Ther"},{"key":"9495_CR70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123\u2013129","journal-title":"Lancet"},{"issue":"26","key":"9495_CR71","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682\u20132695","journal-title":"N Engl J Med"},{"issue":"3","key":"9495_CR72","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","volume":"204","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011;204(3):415\u2013418","journal-title":"J Infect Dis"},{"issue":"1","key":"9495_CR73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2008.09.005","volume":"81","author":"J Chen","year":"2009","unstructured":"Chen J, Wang Z, Guo Y, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009;81(1):88\u201391","journal-title":"Antiviral Res"},{"issue":"1","key":"9495_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","volume":"46","author":"SM Lin","year":"2007","unstructured":"Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46(1):45\u201352","journal-title":"J Hepatol"},{"issue":"6","key":"9495_CR75","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","volume":"50","author":"R Moucari","year":"2009","unstructured":"Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009;50(6):1084\u20131092","journal-title":"J Hepatol"},{"issue":"9","key":"9495_CR76","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MCG.0b013e3181d52946","volume":"44","author":"YK Jung","year":"2010","unstructured":"Jung YK, Kim JH, Lee YS, et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-na\u0131\u00a8ve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010;44(9):653\u2013657","journal-title":"J Clin Gastroenterol"},{"key":"9495_CR77","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1743-422X-8-444","volume":"8","author":"H Lu","year":"2011","unstructured":"Lu H, da Geng Y, Shen F, et al. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study. Virol J 2011;8:444. doi: 10.1186\/1743-422X-8-444 .","journal-title":"Virol J"},{"issue":"10","key":"9495_CR78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001\u20131010","journal-title":"N Engl J Med"},{"issue":"25","key":"9495_CR79","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576\u20132588","journal-title":"N Engl J Med"},{"issue":"3","key":"9495_CR80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2893.2011.01542.x","volume":"19","author":"R Idilman","year":"2012","unstructured":"Idilman R, Cinar K, Seven G, et al. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012;19(3):220\u2013226","journal-title":"J Viral Hepat"},{"issue":"4","key":"9495_CR81","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","volume":"37","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37(4):748\u2013755","journal-title":"Hepatology"},{"issue":"5","key":"9495_CR82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1478-3231.2011.02490.x","volume":"31","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Wang Y, Liaw YF, Hou J, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011;31(5):676\u2013684","journal-title":"Liver Int"},{"issue":"2","key":"9495_CR83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL. Kew Yoon S et al. Entecavir treatment for up to 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51(2):422\u2013430","journal-title":"Hepatology"},{"issue":"23","key":"9495_CR84","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359(23):2442\u20132455","journal-title":"N Engl J Med"},{"issue":"3","key":"9495_CR85","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48(3):750\u2013758","journal-title":"Hepatology"},{"issue":"1","key":"9495_CR86","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","volume":"140","author":"EJ Heathcote","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140(1):132\u2013143","journal-title":"Gastroenterology"},{"issue":"6","key":"9495_CR87","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","volume":"139","author":"TE Vries-Sluijs de","year":"2010","unstructured":"de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139(6):1934\u20131941","journal-title":"Gastroenterology"},{"issue":"2","key":"9495_CR88","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52(2):454\u2013461","journal-title":"Hepatology"},{"issue":"7","key":"9495_CR89","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3\u00a0years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136(7):2169\u20132179","journal-title":"Gastroenterology"},{"issue":"10","key":"9495_CR90","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1111\/j.1365-2893.2011.01473.x","volume":"18","author":"A Gramenzi","year":"2011","unstructured":"Gramenzi A, Loggi E, Micco L, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat 2011;18(10):e468\u2013e474","journal-title":"J Viral Hepat"},{"issue":"4","key":"9495_CR91","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","volume":"35","author":"CY Peng","year":"2012","unstructured":"Peng CY, Lai HC, Li YF, et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35(4):458\u2013468","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"9495_CR92","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","volume":"37","author":"P Lampertico","year":"2003","unstructured":"Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37(4):756\u2013763","journal-title":"Hepatology"},{"issue":"12","key":"9495_CR93","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206\u20131217","journal-title":"N Engl J Med"},{"issue":"26","key":"9495_CR94","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"S Hadziyannis","year":"2005","unstructured":"Hadziyannis S, Tassopoulos N, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Eng J Med 2005;352(26):2673\u20132681","journal-title":"N Eng J Med"},{"issue":"6","key":"9495_CR95","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"S Hadziyannis","year":"2006","unstructured":"Hadziyannis S, Tassopoulos N, Heathcote E, et al. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology 2006;131(6):1743\u20131751","journal-title":"Gastroenterology"},{"issue":"3","key":"9495_CR96","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","volume":"143","author":"SJ Hadziyannis","year":"2012","unstructured":"Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-Negative patients with chronic hepatitis B who stop long-term treatment with Adefovir. Gastroenterology 2012;143(3):629\u2013636","journal-title":"Gastroenterology"},{"issue":"17","key":"9495_CR97","first-page":"1011","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(17):1011\u20131020","journal-title":"N Engl J Med"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-013-9495-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9495-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T11:38:46Z","timestamp":1688902726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-013-9495-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["9495"],"URL":"https:\/\/doi.org\/10.1007\/s12072-013-9495-3","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}